Overview

A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.

Status:
Not yet recruiting

Trial end date:
2028-04-01

Target enrollment:

Participant gender:

Summary

The study is a multicenter, open-label, phase Ib/II study to evaluate the efficacy and safety of docetaxel for injection (albumin-bound) (HB1801) and SG001 in combination with cisplatin and simultaneous radiotherapy versus paclitaxel in combination with cisplatin and simultaneous radiotherapy for locally advanced unresectable esophageal squamous carcinoma.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Treatments:

Docetaxel
Paclitaxel